Histone deacetylase inhibition sensitizes TP53-mutated B-cell precursor acute lymphoblastic leukemia to chemotherapy
To determine how histone deacetylation inhibition synergizes with cytarabine, we performed RNA sequencing investigating which genes are affected in response to romidepsin, cytarabine or the combination Overall design: Nalm6 and RCH-ACV cells were either left untreated or treated for 16 h 2 nM romidepsin, 200 nM Cytarabine or a combination of both drugs, after which mRNA is isolated and transcriptome analyzed